207 related articles for article (PubMed ID: 30394948)
1. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis.
Flexner C; Thomas DL; Swindells S
Curr Opin HIV AIDS; 2019 Jan; 14(1):13-20. PubMed ID: 30394948
[TBL] [Abstract][Full Text] [Related]
2. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
Flexner C; Owen A; Siccardi M; Swindells S
Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
[TBL] [Abstract][Full Text] [Related]
3. Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.
Jacobson JM; Flexner CW
Curr Opin HIV AIDS; 2017 Jul; 12(4):343-350. PubMed ID: 28368868
[TBL] [Abstract][Full Text] [Related]
4. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
5. Long-acting antiviral agents for HIV treatment.
Margolis DA; Boffito M
Curr Opin HIV AIDS; 2015 Jul; 10(4):246-52. PubMed ID: 26049949
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus infection challenges: Current therapeutic limitations and strategies for improved management through long-acting injectable formulation.
Tanushree ; Sharma A; Monika ; Singh RP; Jhawat V
Rev Med Virol; 2024 Jul; 34(4):e2563. PubMed ID: 38886179
[TBL] [Abstract][Full Text] [Related]
7. Long-acting rilpivirine for HIV prevention.
Jackson A; McGowan I
Curr Opin HIV AIDS; 2015 Jul; 10(4):253-7. PubMed ID: 26049950
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral implants for treatment and prevention of HIV infection.
Flexner C
Curr Opin HIV AIDS; 2018 Jul; 13(4):374-380. PubMed ID: 29794816
[TBL] [Abstract][Full Text] [Related]
9. Delivery of long-acting injectable antivirals: best approaches and recent advances.
Hickey MB; Merisko-Liversidge E; Remenar JF; Namchuk M
Curr Opin Infect Dis; 2015 Dec; 28(6):603-10. PubMed ID: 26524333
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting Antiretrovirals: Where Are We now?
Nyaku AN; Kelly SG; Taiwo BO
Curr HIV/AIDS Rep; 2017 Apr; 14(2):63-71. PubMed ID: 28303548
[TBL] [Abstract][Full Text] [Related]
11. Implementation of long-acting antiretroviral therapy in low-income and middle-income countries.
Cresswell FV; Lamorde M
Curr Opin HIV AIDS; 2022 May; 17(3):127-134. PubMed ID: 35439787
[TBL] [Abstract][Full Text] [Related]
12. Long-Acting HIV Drugs for Treatment and Prevention.
Gulick RM; Flexner C
Annu Rev Med; 2019 Jan; 70():137-150. PubMed ID: 30355266
[TBL] [Abstract][Full Text] [Related]
13. Long-acting injectable antiretrovirals for HIV treatment and prevention.
Spreen WR; Margolis DA; Pottage JC
Curr Opin HIV AIDS; 2013 Nov; 8(6):565-71. PubMed ID: 24100877
[TBL] [Abstract][Full Text] [Related]
14. The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?
Scarsi KK; Swindells S
J Int Assoc Provid AIDS Care; 2021; 20():23259582211009011. PubMed ID: 33902356
[TBL] [Abstract][Full Text] [Related]
15. The promise and pitfalls of long-acting injectable agents for HIV prevention.
Landovitz RJ; Kofron R; McCauley M
Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
[TBL] [Abstract][Full Text] [Related]
16. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
[TBL] [Abstract][Full Text] [Related]
17. Design strategies for long-acting anti-HIV pharmaceuticals.
Sang Y; Ding L; Zhuang C; Chen F
Curr Opin Pharmacol; 2020 Oct; 54():158-165. PubMed ID: 33176247
[TBL] [Abstract][Full Text] [Related]
18. Transitioning Long-Acting Products to a Generic Marketplace: What's Missing?
Brown Ripin DH; Catlin K; Lewis L; Resar D; Amole C; Bollinger RC; Flexner C
Clin Infect Dis; 2022 Nov; 75(Suppl 4):S557-S561. PubMed ID: 36410379
[TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
